Mutational landscape and tyrosine kinase inhibitor sensitivity in <i>EGFR</i> L833 and H835 mutated non–small cell lung cancer
This study highlights the unique molecular characteristics of NSCLC patients with EGFR L833 and H835 mutations and confirms their sensitivity to all generations of EGFR-TKIs, with PFS comparable to L858R, providing real-world evidence for clinical decision-making.
Authors
- Zhiqi Liu (ORCID: https://orcid.org/0000-0002-5347-0773)
- Dongxia Ren (ORCID: https://orcid.org/0000-0003-1308-5130)
- Qiuxiang Ou (ORCID: https://orcid.org/0000-0002-2961-2057)
- Xiaotian Zhao (ORCID: https://orcid.org/0000-0003-3823-3232)
- Jiaohui Pang (ORCID: https://orcid.org/0009-0003-0689-560X)
- Nong Yang (ORCID: https://orcid.org/0000-0003-0997-3645)
- Hua Bao (ORCID: https://orcid.org/0000-0001-5774-8755)
- Long Huang (ORCID: https://orcid.org/0000-0003-4925-5162)
- Xiaoying Wu (ORCID: https://orcid.org/0000-0002-7913-118X)
- Peng Huang (ORCID: https://orcid.org/0000-0001-6501-9552)
- Hanlin Chen (ORCID: https://orcid.org/0000-0002-7868-6028)
- Fanxu Zeng
- Chengchuan Jiang
Institutions
- Nanchang University (CN)
- Second People Hospital of Hunan (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- Genesee Community College (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-08-31
- DOI
- https://doi.org/10.1002/cncr.70063
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00